RxDoctor Payments Data

Kasha Benton, MD

Neurology · Huntsville, ALNPI 1730524919

Payments from drug & device makers

$12,798in general payments, 2019–2025

Across 821 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Novartis$972
  • Amgen$692
  • UCB, Inc.$575
  • MDD US Operations, LLC$541
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$981%
  • Food & beverage$12,70099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)213$2,472
Pfizer123$1,456
Novartis57$972
Amgen(2 entities)39$692
UCB, Inc.43$575
MDD US Operations, LLC10$541
Acadia Pharmaceuticals Inc27$494
AstraZeneca23$492
Neurocrine Biosciences, Inc.18$426
Biohaven Pharmaceuticals, Inc.14$319
CSL Behring10$268
Lilly USA, LLC17$266
Neurelis, Inc.17$259
Acorda Therapeutics, Inc13$252
Otsuka America Pharmaceutical, Inc.12$250
SK Life Science, Inc.16$237
Upsher-smith Laboratories LLC13$231
Lundbeck LLC12$203
Teva Pharmaceuticals USA, Inc.12$179
Sunovion Pharmaceuticals Inc.13$174
Biogen11$161
Genentech USA, Inc.8$160
Biohaven Pharmaceutical Holding Company Ltd.8$147
Eisai Inc.7$120
EMD Serono, Inc.6$104
Adamas Pharmaceuticals, Inc.7$102
Axsome Therapeutics, Inc.4$83
Takeda Pharmaceuticals U.S.A., Inc.4$83
Avanir Pharmaceuticals, Inc.4$67
Grifols USA, LLC3$58
Johnson & Johnson2$55
Supernus Pharmaceuticals, Inc.3$55
Jazz Pharmaceuticals Inc.3$53
Amneal Pharmaceuticals LLC4$53
Portola Pharmaceuticals, LLC3$53
Xeris Pharmaceuticals, Inc.3$49
Greenwich Biosciences, Inc.3$47
Merz Pharmaceuticals, LLC2$47
Assertio Therapeutics, Inc.3$45
TG Therapeutics, Inc.2$41
Impel Pharmaceuticals Inc.2$41
Aquestive Therapeutics, Inc.2$32
Boston Scientific1$31
Aucta Pharmaceuticals, Inc.5$29
Kyowa Kirin, Inc.2$29
Averitas Pharma Inc.1$24
Sanofi1$23
Catalyst Pharmaceuticals, Inc.1$22
Almatica Pharma LLC1$21
Bristol Myers Squibb1$20
Livanova USA, Inc.1$19
Sumitomo Pharma America, Inc.1$19
Immedica Pharma US, Inc.1$18
Zogenix Inc.1$17
Avion Pharmaceuticals1$16
Currax Pharmaceuticals LLC1$15
Cycle Pharmaceuticals Inc1$15
GE HealthCare1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$14
Harmony Biosciences LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,798 in reported general payments places this provider in the 60th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$106,748
Medicare patients
355
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate88$108,758
Emgality PenGalcanezumab-Gnlm101$77,748
BriviactBrivaracetam33$45,275
UbrelvyUbrogepant26$29,841
QuliptaAtogepant25$26,699
Aimovig AutoinjectorErenumab-Aooe25$25,242
XcopriCenobamate19$20,087
Carbamazepine ErCarbamazepine136$12,063
Rivastigmine32$10,584
Lamotrigine ErLamotrigine11$4,419
Levetiracetam160$4,277
Gabapentin309$3,927
Lacosamide23$3,828
Memantine Hcl94$2,987
Pregabalin80$2,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$1,456$108,75888 claims
AbbVieUbrelvy, Qulipta$2,472$56,53951 claims
UCB, Inc.Briviact$575$45,27533 claims
SK Life Science, Inc.Xcopri$237$20,08719 claims
Upsher-smith Laboratories LLCTopiramate$231$66040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 neurology providers in Alabama.

Other neurology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →